COVID-19 Neuro Databank-Biobank | NYU Langone Health

Skip to Main Content
Division of Biostatistics Research COVID-19 Neuro Databank-Biobank

COVID-19 Neuro Databank-Biobank

The COVID-19 Neuro Databank-Biobank (The NeuroCOVID Project), funded by the National Institute of Neurological Disorders and Stroke, part of the National Institutes of Health, has been initiated at NYU Langone Health. We will create and maintain a national resource documenting and studying neurological complications of coronavirus disease (COVID-19), the illness caused by infection with the SARS-CoV-2 novel coronavirus. Together, these efforts comprise the NeuroCOVID Project.

If you are a member of a participating study site, please directly log into OpenREDCap with your NYU Kerberos ID for data entry and iLab with your NYU Kerberos ID or other institution credentials for biospecimen shipment.

The NeuroCOVID Project

The NeuroCOVID Project will encompass a REDCap database, the Neuro Databank (the databank), to receive and store information on patients who have COVID-19, and a biorepository, the Neuro Biobank (the biobank), to receive, track, store, and distribute biosamples from patients who have COVID-19.

The databank will include de-identified patient data; individuals will be identified only by a globally unique identifier (GUID) to ensure that no protected health information is transmitted to the databank. The GUID will enable de-identified linkage of individual participants’ data, linkage of maternal and child data, and linkage to patients’ specimens in the biobank.

COVID-19 Neuro Databank

The databank will collect information on adults, children, and neonates with confirmed COVID-19 infection. We will assess new neurological complications of COVID-19, as well as potential exacerbation of pre-existing neurological conditions. We will assess pregnancy outcomes among pregnant women and their babies, as well as symptoms, conditions, and outcomes among children and adults.

COVID-19 Neuro Biobank

The biobank will collect a wide variety of biosamples, including blood, plasma, cerebrospinal fluid, and tissue, from patients who have COVID-19 and experience neurological complications. The majority of these specimens will be pre-existing, avoiding the need for additional collection. We will also be able to track the location of biosamples that may have been submitted to other repositories for inventory management.

National Resource of Pooled COVID-19 Neurological Event Data

The Atlantic Highlights the NeuroCOVID Project

NeuroCOVID Steering Committee

The NeuroCOVID Steering Committee comprises experts in neurology, infectious diseases, statistics, and other relevant disciplines and will provide long-term guidance and strategic planning to the NeuroCOVID Project.

The Steering Committee consists of the following members:

Andrea B. Troxel, ScD, NYU Grossman School of Medicine
Eva Petkova, PhD, NYU Grossman School of Medicine
Jennifer A. Frontera, MD, NYU Grossman School of Medicine
Shadi Yaghi, MD, Brown University
Jennifer Beierlein, PhD, National Institute of Neurological Disorders and Stroke
Rebecca Hommer, MD, National Institute of Neurological Disorders and Stroke
Barbara Karp, MD, National Institute of Neurological Disorders and Stroke
Carolina Mendoza-Puccini, MD, National Institute of Neurological Disorders and Stroke
Clinton Wright, MD, MS, National Institute of Neurological Disorders and Stroke
Adarsh Bhimraj, MD, Cleveland Clinic
Sherry Chou, MD, MMSc, University of Pittsburgh Medical Center
Ericka Fink, MD, MS, University of Pittsburgh Medical Center
Alla Guekht, MD, PhD, Russian National Research Medical University
Lyell Jones Jr., MD, Mayo Clinic
Molly McNett, PhD, RN, Ohio State University
Natalia Rost, MD, Harvard Medical School
Jose Suarez, MD, Johns Hopkins University
Andrea Winkler, MD, PhD, Technical University of Munich

NeuroCOVID Project Publications and Media

Guarino B and Sellers FS. Scientists begin to unravel the mysteries of the coronavirus and brains. The Washington Post. June 7, 2021.

Rodriguez A. Dr. Anthony Fauci aims to answer ‘a lot of important questions’ about ‘COVID long-haulers’ in new nationwide initiative. USA Today. February 24, 2021.

Lyles A. NINDS launches a database to assess neurologic events associated with COVID-19. Neurology Today. February 17, 2021.

Fyfe I. COVID-19 database launched in the USA. Nat Rev Neurol. 2021. DOI.

Sim S. NYU Grossman School of Medicine receives $2.2M to launch Covid neuro-symptoms database. Crain’s Health Plus New York. January 28, 2021. (Subscription required.)

NeuroFrontiers: Expanding on the Neurologic Effects of COVID-19, an interview featuring Dr. Jennifer Frontera. ReachMD.

NeuroFrontiers: Shedding Light on the Brain After COVID-19: Assessing the Spectrum of Neurological Risk, an interview featuring Dr. Jennifer Frontera. ReachMD.

Contact Us

Both the databank and biobank are envisioned as a national resource. Interested researchers may submit requests for the use of data and biosamples to the NeuroCOVID Steering Committee. We are prepared to accept data and specimens, pending finalization of contracts for site engagement, data use, and biospecimen transfer.

Please check back soon for an application and instructions for joining us as contributing clinical partners in studying the neurological complications of COVID-19 infection. If you would like more information or have questions, please contact Cecile Norris, project manager, at, or Sharon B. Meropol, MD, program director, at